Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Microfluidics for Circulating Biomarkers Summit 2019

Dominique PV de Kleijn's Biography



Dominique PV de Kleijn, Professor Experimental Vascular Surgery, Professor Netherlands Heart Institute, University Medical Center Utrecht, The Netherlands

Prof. Dr. Dominique PV de Kleijn is molecular biologist and chemist and professor of Exp. Vascular Surgery at UMC Utrecht and professor at the Netherlands Heart Institute. From 2012 to 2016, he was Research Professor of Surgery at NUS/NUHS and preclinical director of the Cardiovascular Research Institute (CVRI) Singapore. He was until 2016 professor of Cardiovascular Immunology and co-chair of Experimental Cardiology at UMC Utrecht. Since 1997 he is coordinating cardiovascular research from basic science, animal myocardial infarction and atherosclerotic studies (pig and sheep) towards clinical biobanking studies. His research interests are: The innate immune system in cardiovascular disease and atherosclerosis & Biomarkers predictive for primary & secondary events with a focus on plasma extracellular vesicles. He has more then 275 publications and a H-factor of 78.

Dominique PV de Kleijn Image

Extracellular Vesicles For Early Diagnosis of Stable Angina in a General Practitioner Environment

Thursday, 10 October 2019 at 15:30

Add to Calendar ▼2019-10-10 15:30:002019-10-10 16:30:00Europe/LondonExtracellular Vesicles For Early Diagnosis of Stable Angina in a General Practitioner Environment Microfluidics for Circulating Biomarkers Summit 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Cardiovascular Disease (CVD) is with cardiovascular events of Ischemic Heart Disease (IHD) and Stroke, the number 1 and 2 cause of death in the world.

Stable Coronary Artery Disease (SCAD) or Stable Angina (SA) is one of the entities of IHD but in contrast to hsTroponins for myocardial infarction, there is no bloodmarker for quick and easy diagnosis.
SA is a very common disease (10-14% in the age group of 65-84 years) and a serious pathology resulting in a 4-6 times higher change of cardiovascular events like myocardial infarction. SA diagnosis is challenging, as many patients present with atypical symptoms with women have a different symptom sensation than men. This results in that 90% of women with chest pain suspected for SA are referred to the hospital by the GP do not have SA.
A simple SA early diagnosis blood test is expected to allow GPs to improve their assessment and decisons to refer or not to refer a patient to a cardiologist, reducing care costs and efficiency of care trajectories.
We have now a validated protein signature measured  in subsets of plasma extracellular vesicle (EV) that can accurately diagnose SA in women using 25 ul plasma. We simplified and validated this EV-based blood assay and will now develop a microfluidic device to isolate plasma EV subsets and determine EV biomarker levels that will make early diagnosis of SA in the GP environment possible.
Such a microfluidic device will also be very useful in other POC applications using EV subsets in diagnosis and prognosis of cardiovascular disease in GP or ambulance.


Add to Calendar ▼2019-10-10 00:00:002019-10-10 00:00:00Europe/LondonMicrofluidics for Circulating Biomarkers Summit 2019Microfluidics for Circulating Biomarkers Summit 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com